GLP-1 receptor agonists are associated with a higher risk of hair loss compared with SGLT-2 inhibitors (about 7 per 1,000 person-years vs 5 per 1,000) and compared with DPP-4 inhibitors (roughly 7 vs 3.9 per 1,000 person-years), with most cases being temporary and attributed to non-scarring hair shedding.

Potential mechanisms discussed include rapid weight loss, nutritional deficiencies (iron or zinc), and hormonal changes, though the exact cause remains unclear and warrants further study.

The finding aligns with FDA observations, and clinicians and patients should be aware of this possible side effect as part of shared decision-making.

The article provides the association but offers no specific management or guidance beyond informing patients about the potential risk.

Authors note the study adds systematic evidence to prior safety signals while emphasizing that the absolute risk is small.

The excerpt does not include detailed data (sample sizes or statistics) beyond the stated rarity and existence of the effect.

The piece includes background on author Alice Barraclough, but this is ancillary to the study findings.

Related, separate research hints at possible reductions in hospital admissions for alcohol use with these meds, though evidence is limited and inconclusive.

Findings sit within ongoing regulatory inquiries and prior case reports, underscoring the need for more research on biological mechanisms and risk factors.

Experts stress the absolute risk is low and that rapid weight loss and nutritional issues could drive temporary shedding; the study does not clarify whether effects are reversible or persistent after treatment.

Funding came from NIH; some authors disclosed industry relationships; ethical review was waived by the University of Pennsylvania IRB.

The article credits Health and Me as the source, with author Rachel V. Thomas, updated July 23, 2026.